This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the ELREXFIO®▼ (elranatamab) Summary of Product Characteristics for Great Britain and Northern Ireland. For ELREXFIO®▼ (elranatamab) Prescribing Information for Great Britain and Northern Ireland click here.
MM treatment becomes more complex with each line of therapy, as increased likelihood of treatment resistance leads to shorter remissions1-3
Each multiple myeloma relapse is typically accompanied by:1-4
In a retrospective analysis of 4,997 patients with MM, average remission times diminished with each line of therapy3
Adapted from Yong K, et al.3
*Paraprotein is the monoclonal protein produced by plasma cells.2
Analysis Background
Based on data from a retrospective analysis of patient characteristics, treatment durations and outcomes, and symptom burden in 4,997 patient charts from Belgium, France, Germany, Italy, Spain, Switzerland and the UK. Analysis was performed in 2014.2,3
In a retrospective analysis of 275 patients with MM refractory to a CD38 mAb, subsequent lines of therapy (2nd to 5th) were associated with diminished clinical outcomes compared to 1st line5
Adapted from Gandhi UH, et al.5
Study Background
The MAMMOTH study was a US multicentre, retrospective study of 275 patients conducted between January 2017 and June 2018 to investigate the natural history and outcomes of patients with MM refractory to CD38 mAbs.5
Patients in the MAMMOTH study were classified into 3 groups:5
References:
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024